Skip to main content
SpringerLink
Log in

Desvenlafaxine extended-release tablets in major depressive disorder and menopause-associated hot flushes: a profile of its use

  • Adis Drug Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Oral desvenlafaxine extended-release [Deller® (Brazil); Pristiq® (USA)] is a second-generation, selective serotonin-noradrenalin reuptake inhibitor that is indicated for the treatment of major depressive disorder (MDD) in adults. In this population, desvenlafaxine is an effective and generally well tolerated treatment, significantly improving symptoms of depression and functional outcomes compared with placebo in 8-week double-blind trials, with these benefits maintained during longer-term therapy. In addition, desvenlafaxine is an effective and generally well tolerated treatment in postmenopausal women with vasomotor symptoms (VMS), significantly reducing the number and severity of hot flushes during 12-week trials, with these benefits maintained during longer-term therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lepine J-P, Briley M. The increasing burden of depression. Neuropsychiatr Dis Treat. 2011;7(Suppl 1):3–7.

    PubMed  PubMed Central  Google Scholar 

  2. Ferrari AJ, Charlson FJ, Norman RE, et al. The epidemiological modelling of major depressive disorder: application for the Global Burden of Disease study 2010. PLoS Med. 2013;8(7):e69637.

    Article  CAS  Google Scholar 

  3. Belmaker RH, Agam R. Major depressive disorder. N Engl J Med. 2008;358(1):55–68.

    Article  CAS  PubMed  Google Scholar 

  4. Deecher DC, Dorries K. Understanding the pathophysiology of vasomotor symptoms (hot flushes and night sweats) that occur in perimenopause, menopause, and postmenopause life stages. Arch Womens Ment Health. 2007;10:247–57.

    Article  CAS  PubMed  Google Scholar 

  5. Qaseem A, Barry MJ, Kansagara D, et al. Nonpharmacologic versus pharmacologic treatment of adult patients with major depressive disorder: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2016;164:350–9.

    Article  PubMed  Google Scholar 

  6. Deller (desvenlafaxine succinate monohydrate): Brazilian information for health professionals [in Portuguese]. São Paulo: Aché Laboratórios Farmacêuticos S.A; 2016.

  7. Pristiq® (desvenlafaxine) extended-release tablets, for oral use: US prescribing information: Philadelphia (PA): Pfizer Inc.; 2017.

  8. Boyer P, Montgomery S, Lepola U, et al. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol. 2008;23(5):243–53.

    Article  PubMed  Google Scholar 

  9. Iwata N, Tourian KA, Hwang E, et al. Efficacy and safety of desvenlafaxine 25 and 50 mg/day in a randomized, placebo-controlled study of depressed outpatients. J Psychiatr Pract. 2013;19(1):5–14.

    Article  PubMed  Google Scholar 

  10. Liebowitz MR, Manley AL, Padmanabhan SK, et al. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin. 2008;24(7):1877–90.

    Article  CAS  PubMed  Google Scholar 

  11. Tourian KA, Padmanabhan SK, Groark J, et al. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Clin Ther. 2009;31(Pt 1):1405–23.

    Article  CAS  PubMed  Google Scholar 

  12. Clayton AH, Tourian KA, Focht K, et al. Desvenlafaxine 50 and 100 mg/d versus placebo for the treatment of major depressive disorder: a phase 4, randomized controlled trial. J Clin Psychiatry. 2015;76(5):562–9.

    Article  PubMed  Google Scholar 

  13. Clayton AH, Kornstein SG, Dunlop BW, et al. Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry. 2013;74(10):1010–7.

    Article  CAS  PubMed  Google Scholar 

  14. Dunlop BW, Reddy S, Yang L, et al. Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo. J Clin Psychopharmacol. 2011;31(5):569–76.

    Article  CAS  PubMed  Google Scholar 

  15. Kornstein SG, Jiang Q, Reddy S, et al. Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry. 2010;71(8):1088–96.

    Article  CAS  PubMed  Google Scholar 

  16. Soares CN, Thase ME, Clayton A, et al. Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder. Menopause. 2010;17(4):700–11.

    PubMed  Google Scholar 

  17. Carrasco JL, Kornstein SG, McIntyre RS, et al. An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorder. Int Clin Psychopharmacol. 2016;31(3):134–46.

    Article  PubMed  Google Scholar 

  18. Kornstein SG, Clayton AH, Soares CN, et al. Analysis by age and sex of efficacy data from placebo-controlled trials of desvenlafaxine in outpatients with major depressive disorder. J Clin Psychopharmacol. 2010;30(3):294–9.

    Article  CAS  PubMed  Google Scholar 

  19. Mosca D, Zhang M, Prieto R, et al. Efficacy of desvenlafaxine compared with placebo in major depressive disorder patients by age group and severity of depression at baseline. J Clin Psychopharmacol. 2017;37(2):182–92.

    Article  CAS  PubMed  Google Scholar 

  20. McIntyre RS, Fayyad R, Mackell JA, et al. Effect of metabolic syndrome and thyroid hormone on efficacy of desvenlafaxine 50 and 100 mg/d in major depressive disorder. Curr Med Res Opin. 2016;32(3):587–99.

    Article  CAS  PubMed  Google Scholar 

  21. Rosenthal JZ, Boyer P, Vialet C, et al. Efficacy and safety of desvenlafaxine 50 mg/d for prevention of relapse in major depressive disorder: a randomized controlled trial. J Clin Psychiatry. 2013;74(2):158–66.

    Article  CAS  PubMed  Google Scholar 

  22. Boyer P, Vialet C, Hwang E, et al. Efficacy of desvenlafaxine 50 mg/d versus placebo in the long-term treatment of major depressive disorder: a randomized, double-blind trial. Prim Care Companion CNS Disord. 2015. doi:10.4088/PCC.14m01711.

    PubMed  PubMed Central  Google Scholar 

  23. Archer DF, Seidman L, Constantine GD, et al. A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. Am J Obstet Gynecol. 2009;200(2):172.e1–10.

    Article  Google Scholar 

  24. Archer DF, Dupont CM, Constantine GD, et al. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety. Am J Obstet Gynecol. 2009;200(3):238.e1–10.

    Article  Google Scholar 

  25. Bouchard P, Panay N, de Villiers TJ, et al. Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms. Climacteric. 2012;15(1):12–20.

    Article  CAS  PubMed  Google Scholar 

  26. Pinkerton JV, Constantine G, Hwang E, et al. Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial. Menopause. 2013;20(1):28–37.

    Article  PubMed  Google Scholar 

  27. Speroff L, Gass M, Constantine G, et al. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol. 2008;111(1):77–87.

    Article  CAS  PubMed  Google Scholar 

  28. Pinkerton JV, Archer DF, Guico-Pabia CJ, et al. Maintenance of the efficacy of desvenlafaxine in menopausal vasomotor symptoms: a 1-year randomized controlled trial. Menopause. 2013;20(1):38–46.

    Article  PubMed  Google Scholar 

  29. Cheng RJ, Dupont C, Archer DF, et al. Effect of desvenlafaxine on mood and climacteric symptoms in menopausal women with moderate to severe vasomotor symptoms. Climacteric. 2013;16(1):17–27.

    Article  CAS  PubMed  Google Scholar 

  30. Archer DF, Pinkerton JV, Guico-Pabia CJ, et al. Cardiovascular, cerebrovascular, and hepatic safety of desvenlafaxine for 1 year in women with vasomotor symptoms associated with menopause. Menopause. 2013;20(1):47–56.

    PubMed  Google Scholar 

  31. Nutt DJ, Davidson JRT, Gelenberg AJ, et al. International consensus statement of major depressive disorder. J Clin Psychiatry. 2010;71(Suppl E1):e08.

  32. North American Menospause Society. Nonhormonal management of menopause-asscoiated vasomotor symptoms: 2015 position statement of the North American Menopause Society. Menopause. 2015;22(11):1–18.

    Google Scholar 

Download references

Acknowledgements

The manuscript was reviewed by: N. Cebotarenco, Coalition for Rational and Safe Use of Medicines (CoRSUM), Chişinău, Republic of Moldova; S. Saluja, Saran Ashram Hospital, Dayalbagh, Agra, India. During the peer review process, the marketing authorization holder of desvenlafaxine was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Lesley J. Scott

Authors
  1. Lesley J. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lesley J. Scott.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

Lesley Scott is an employee of Adis/Springer, is responsible for the article content and declares no conflicts of interest.

Additional information about this Adis Drug Review can be found at http://www.medengine.com/Redeem/30FBF0605D9F6BA0.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Scott, L.J. Desvenlafaxine extended-release tablets in major depressive disorder and menopause-associated hot flushes: a profile of its use. Drugs Ther Perspect 33, 449–454 (2017). https://doi.org/10.1007/s40267-017-0439-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-017-0439-1

Search

Navigation